Matters arising: On the cost-effectiveness for the Italian National Health Service of nab-paclitaxel plus gemcitabine vs gemcitabine alone in metastatic pancreatic cancer.
作者信息
Lazzaro Carlo
机构信息
Studio di Economia Sanitaria, Via Stefanardo da Vimercate, 19, Milan, 20128, Italy.
Biology and Biotechnologies Department "Lazzaro Spallanzani", University of Pavia, Pavia, 27100, Italy.
出版信息
J Egypt Public Health Assoc. 2024 Dec 2;99(1):30. doi: 10.1186/s42506-024-00179-3.
Abstract
摘要
相似文献
1
Matters arising: On the cost-effectiveness for the Italian National Health Service of nab-paclitaxel plus gemcitabine vs gemcitabine alone in metastatic pancreatic cancer.出现的问题：关于纳米白蛋白结合型紫杉醇联合吉西他滨与单用吉西他滨治疗转移性胰腺癌对意大利国家医疗服务体系的成本效益。
J Egypt Public Health Assoc. 2024 Dec 2;99(1):30. doi: 10.1186/s42506-024-00179-3.
2
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study.一项关于白蛋白结合型紫杉醇（纳米白蛋白紫杉醇）联合吉西他滨与单用吉西他滨治疗转移性胰腺癌患者的意大利成本效益分析：APICE研究
Expert Rev Pharmacoecon Outcomes Res. 2018 Aug;18(4):435-446. doi: 10.1080/14737167.2018.1464394. Epub 2018 Apr 20.
3
-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial.紫杉醇联合吉西他滨治疗转移性胰腺癌：MPACT试验西欧队列的亚组分析
Onco Targets Ther. 2017 Feb 2;10:591-596. doi: 10.2147/OTT.S124097. eCollection 2017.
4
Comparative effectiveness and resource utilization of -paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting.在美国社区环境中，紫杉醇加吉西他滨与FOLFIRINOX或吉西他滨用于转移性胰腺腺癌一线治疗的疗效比较及资源利用情况。
Cancer Manag Res. 2017 Apr 21;9:141-148. doi: 10.2147/CMAR.S126073. eCollection 2017.
5
nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial.纳米白蛋白结合型紫杉醇联合吉西他滨治疗转移性胰腺腺癌：III期MPACT试验的澳大利亚亚组分析
Asia Pac J Clin Oncol. 2018 Oct;14(5):e325-e331. doi: 10.1111/ajco.12999. Epub 2018 Jun 22.
6
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial.转移性胰腺癌诱导治疗后交替吉西他滨加 nab-紫杉醇和单纯吉西他滨与连续吉西他滨加 nab-紫杉醇治疗（ALPACA）：一项多中心、随机、开放标签、2 期临床试验。
Lancet Gastroenterol Hepatol. 2024 Oct;9(10):935-943. doi: 10.1016/S2468-1253(24)00197-3. Epub 2024 Aug 16.
7
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.白蛋白结合型紫杉醇联合吉西他滨治疗转移性胰腺癌：III 期临床试验的长期生存结果。
J Natl Cancer Inst. 2015 Jan 31;107(2). doi: 10.1093/jnci/dju413. Print 2015 Feb.
8
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.FOLFIRINOX 对比吉西他滨联合白蛋白紫杉醇作为转移性胰腺导管腺癌一线化疗的比较。
JAMA Netw Open. 2022 Jun 1;5(6):e2216199. doi: 10.1001/jamanetworkopen.2022.16199.
9
Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer.比较FOLFIRINOX、白蛋白结合型紫杉醇联合吉西他滨、吉西他滨和S-1治疗转移性胰腺癌的成本效益。
Mol Clin Oncol. 2017 Jul;7(1):125-130. doi: 10.3892/mco.2017.1278. Epub 2017 May 30.
10
Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.比较一线治疗转移性胰腺癌时，使用nab-紫杉醇联合吉西他滨或 FOLFIRINOX 的治疗模式、资源利用和医疗成本。
Expert Rev Clin Pharmacol. 2017 May;10(5):559-565. doi: 10.1080/17512433.2017.1302330. Epub 2017 Apr 19.
本文引用的文献
1
Framework for developing cost-effectiveness analysis threshold: the case of Egypt.制定成本效益分析阈值的框架：以埃及为例。
J Egypt Public Health Assoc. 2024 Jun 3;99(1):12. doi: 10.1186/s42506-024-00159-7.
2
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study.一项关于白蛋白结合型紫杉醇（纳米白蛋白紫杉醇）联合吉西他滨与单用吉西他滨治疗转移性胰腺癌患者的意大利成本效益分析：APICE研究
Expert Rev Pharmacoecon Outcomes Res. 2018 Aug;18(4):435-446. doi: 10.1080/14737167.2018.1464394. Epub 2018 Apr 20.
3
The NICE cost-effectiveness threshold: what it is and what that means.英国国家卫生与临床优化研究所（NICE）的成本效益阈值：是什么以及意味着什么。
Pharmacoeconomics. 2008;26(9):733-44. doi: 10.2165/00019053-200826090-00004.
4
Markov models in medical decision making: a practical guide.医学决策中的马尔可夫模型：实用指南。
Med Decis Making. 1993 Oct-Dec;13(4):322-38. doi: 10.1177/0272989X9301300409.
Zotero 插件